Radioactive drug for advanced prostate cancer
Part of Cancer clinical trials.
This trial tests a new radioactive drug (161Tb-NYM032) for men with advanced prostate cancer that has stopped responding to hormone therapy and has spread. The drug aims to find and kill cancer cells while limiting harm to healthy tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are male and at least 18 years old.
- You have a type of advanced prostate cancer that no longer responds to hormone therapy and has spread to other parts of the body (called mCRPC).
- A special PET/CT scan must show your prostate cancer is taking up a tracer called 68Ga-NYM032, meaning the cancer cells are active.
- You have already tried at least one hormone drug (like enzalutamide or abiraterone) or one chemotherapy (like docetaxel), or you cannot take chemotherapy.
- Your blood counts and liver/kidney function must be in a safe range (white blood cells ≥3.5, platelets ≥100, hemoglobin ≥90, and liver enzymes no more than 3 times the normal limit).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an early-stage trial testing a new radioactive treatment (161Tb-PSMA) for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The treatment targets cancer cells using a radioactive metal that may be more effective than older similar treatments.
This trial tests a new drug combination that uses a radioactive molecule to find and treat prostate cancer cells that have spread and are no longer responding to hormone therapy. It may be an option for men with a specific protein called PSMA on their cancer cells.
This trial tests an experimental radioactive drug that targets a protein called PSMA found on prostate cancer cells. It aims to see if this drug is safe and can shrink tumors in men with advanced prostate cancer that has not responded to hormone therapy or chemotherapy.
This trial tests a new radioactive drug, Terbium-161 PSMA, for men with a type of advanced prostate cancer that has stopped responding to standard treatments. It may be an option if you have not received a similar radioactive drug before.
This trial tests a new radioactive treatment, [225Ac]Ac-FL-020, for men with metastatic castration-resistant prostate cancer (mCRPC) that has gotten worse despite other treatments. It's for those who have had at least one prior hormone therapy or chemotherapy.
This trial tests a new radioactive drug designed to target and destroy prostate cancer cells. It is for men whose cancer has continued to grow despite hormone therapy and other treatments like enzalutamide or abiraterone.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.